These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

229 related articles for article (PubMed ID: 20538001)

  • 1. Levels of rectal mucosal polyamines and prostaglandin E2 predict ability of DFMO and sulindac to prevent colorectal adenoma.
    Thompson PA; Wertheim BC; Zell JA; Chen WP; McLaren CE; LaFleur BJ; Meyskens FL; Gerner EW
    Gastroenterology; 2010 Sep; 139(3):797-805, 805.e1. PubMed ID: 20538001
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of alpha-difluoromethylornithine on rectal mucosal levels of polyamines in a randomized, double-blinded trial for colon cancer prevention.
    Meyskens FL; Gerner EW; Emerson S; Pelot D; Durbin T; Doyle K; Lagerberg W
    J Natl Cancer Inst; 1998 Aug; 90(16):1212-8. PubMed ID: 9719082
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dose de-escalation chemoprevention trial of alpha-difluoromethylornithine in patients with colon polyps.
    Meyskens FL; Emerson SS; Pelot D; Meshkinpour H; Shassetz LR; Einspahr J; Alberts DS; Gerner EW
    J Natl Cancer Inst; 1994 Aug; 86(15):1122-30. PubMed ID: 8028034
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Role of dietary polyamines in a phase III clinical trial of difluoromethylornithine (DFMO) and sulindac for prevention of sporadic colorectal adenomas.
    Raj KP; Zell JA; Rock CL; McLaren CE; Zoumas-Morse C; Gerner EW; Meyskens FL
    Br J Cancer; 2013 Feb; 108(3):512-8. PubMed ID: 23340449
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Role of obesity in a randomized placebo-controlled trial of difluoromethylornithine (DFMO) + sulindac for the prevention of sporadic colorectal adenomas.
    Zell JA; Lin BS; Madson N; McLaren CE; Gerner EW; Meyskens FL
    Cancer Causes Control; 2012 Oct; 23(10):1739-44. PubMed ID: 22907422
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of eflornithine (CPP-1X)/sulindac combination therapy versus each as monotherapy in patients with familial adenomatous polyposis (FAP): design and rationale of a randomized, double-blind, Phase III trial.
    Burke CA; Dekker E; Samadder NJ; Stoffel E; Cohen A
    BMC Gastroenterol; 2016 Aug; 16(1):87. PubMed ID: 27480131
    [TBL] [Abstract][Full Text] [Related]  

  • 7. DFMO: targeted risk reduction therapy for colorectal neoplasia.
    Laukaitis CM; Gerner EW
    Best Pract Res Clin Gastroenterol; 2011 Aug; 25(4-5):495-506. PubMed ID: 22122766
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Risk of cardiovascular events in a randomized placebo-controlled, double-blind trial of difluoromethylornithine plus sulindac for the prevention of sporadic colorectal adenomas.
    Zell JA; Pelot D; Chen WP; McLaren CE; Gerner EW; Meyskens FL
    Cancer Prev Res (Phila); 2009 Mar; 2(3):209-12. PubMed ID: 19258540
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phospho-sulindac (OXT-328) combined with difluoromethylornithine prevents colon cancer in mice.
    Mackenzie GG; Ouyang N; Xie G; Vrankova K; Huang L; Sun Y; Komninou D; Kopelovich L; Rigas B
    Cancer Prev Res (Phila); 2011 Jul; 4(7):1052-60. PubMed ID: 21464038
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A randomized, placebo-controlled trial of low-dose alpha-difluoromethylornithine in individuals at risk for colorectal cancer.
    Love RR; Jacoby R; Newton MA; Tutsch KD; Simon K; Pomplun M; Verma AK
    Cancer Epidemiol Biomarkers Prev; 1998 Nov; 7(11):989-92. PubMed ID: 9829706
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prostanoids, ornithine decarboxylase, and polyamines in primary chemoprevention of familial adenomatous polyposis.
    Giardiello FM; Casero RA; Hamilton SR; Hylind LM; Trimbath JD; Geiman DE; Judge KR; Hubbard W; Offerhaus GJ; Yang VW
    Gastroenterology; 2004 Feb; 126(2):425-31. PubMed ID: 14762779
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Regulation of transglutaminase activity by polyamines in the gastrointestinal mucosa of rats.
    Wang JY; Viar MJ; Johnson LR
    Proc Soc Exp Biol Med; 1994 Jan; 205(1):20-8. PubMed ID: 7906881
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of Difluoromethylornithine and Aspirin for Treatment of Adenomas and Aberrant Crypt Foci in Patients with Prior Advanced Colorectal Neoplasms.
    Sinicrope FA; Velamala PR; Song LMWK; Viggiano TR; Bruining DH; Rajan E; Gostout CJ; Kraichely RE; Buttar NS; Schroeder KW; Kisiel JB; Larson MV; Sweetser SR; Sedlack RR; Sinicrope SN; Richmond E; Umar A; Della'Zanna G; Noaeill JS; Meyers JP; Foster NR
    Cancer Prev Res (Phila); 2019 Nov; 12(11):821-830. PubMed ID: 31484660
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Difluoromethylornithine plus sulindac for the prevention of sporadic colorectal adenomas: a randomized placebo-controlled, double-blind trial.
    Meyskens FL; McLaren CE; Pelot D; Fujikawa-Brooks S; Carpenter PM; Hawk E; Kelloff G; Lawson MJ; Kidao J; McCracken J; Albers CG; Ahnen DJ; Turgeon DK; Goldschmid S; Lance P; Hagedorn CH; Gillen DL; Gerner EW
    Cancer Prev Res (Phila); 2008 Jun; 1(1):32-8. PubMed ID: 18841250
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Estradiol control of ornithine decarboxylase mRNA, enzyme activity, and polyamine levels in MCF-7 breast cancer cells: therapeutic implications.
    Thomas T; Thomas TJ
    Breast Cancer Res Treat; 1994 Feb; 29(2):189-201. PubMed ID: 8012036
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibition of polyamine synthesis induces p53 gene expression but not apoptosis.
    Li L; Li J; Rao JN; Li M; Bass BL; Wang JY
    Am J Physiol; 1999 Apr; 276(4):C946-54. PubMed ID: 10199827
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Polyamine contents in rectal and buccal mucosae in humans treated with oral difluoromethylornithine.
    Boyle JO; Meyskens FL; Garewal HS; Gerner EW
    Cancer Epidemiol Biomarkers Prev; 1992; 1(2):131-5. PubMed ID: 1306095
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dietary putrescine reduces the intestinal anticarcinogenic activity of sulindac in a murine model of familial adenomatous polyposis.
    Ignatenko NA; Besselsen DG; Roy UK; Stringer DE; Blohm-Mangone KA; Padilla-Torres JL; Guillen-R JM; Gerner EW
    Nutr Cancer; 2006; 56(2):172-81. PubMed ID: 17474863
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A randomized controlled trial of eicosapentaenoic acid and/or aspirin for colorectal adenoma prevention during colonoscopic surveillance in the NHS Bowel Cancer Screening Programme (The seAFOod Polyp Prevention Trial): study protocol for a randomized controlled trial.
    Hull MA; Sandell AC; Montgomery AA; Logan RF; Clifford GM; Rees CJ; Loadman PM; Whitham D
    Trials; 2013 Jul; 14():237. PubMed ID: 23895505
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mucosal polyamine profile in normal and adapting (hypo and hyperplastic) intestine: effects of DFMO treatment.
    Hosomi M; Lirussi F; Stace NH; Vaja S; Murphy GM; Dowling RH
    Gut; 1987; 28 Suppl(Suppl):103-7. PubMed ID: 3121452
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.